Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study
Fiona Blackhall(National Health Service), Kevin Jao(Hôpital du Sacré-Cœur de Montréal), Laurent Greillier(Centre National de la Recherche Scientifique), Byoung Chul Cho(Yonsei University), Konstantin Penkov, Noemı́ Reguart(Hospital Clínic de Barcelona), Margarita Majem(Hospital de Sant Pau), Kristiaan Nackaerts(KU Leuven), Konstantinos Syrigos(National and Kapodistrian University of Athens), Karin Holmskov Hansen(Odense University Hospital), Wolfgang Schuette(Martha-Maria Hospital), Jeremy Cetnar(Oregon Health & Science University), Federico Cappuzzo(Istituti di Ricovero e Cura a Carattere Scientifico), Isamu Okamoto(Kyushu University Hospital), Mustafa Erman(Hacettepe University Hospital), Seppo W. Langer(University of Copenhagen), Terufumi Kato(Kanagawa Prefectural Hospital Organization), Harry J.M. Groen(University Medical Center Groningen), Zhaowen Sun(AbbVie (United States)), Yan Luo(AbbVie (United States)), Poonam Tanwani(AbbVie (United States)), L. Caffrey(AbbVie (United States)), Philip Komarnitsky(AbbVie (United States)), Niels Reinmuth(Asklepios Fachkliniken München-Gauting)
Cited by 250Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis